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Abstract
Background: Patients with inflammatory rheumatic conditions such as rheumatoid arthritis, polymyalgia rheumatica and
ankylosing spondylitis are at increased risk of common comorbidities such as cardiovascular disease, osteoporosis
and anxiety and depression which lead to increased morbidity and mortality. These associated morbidities are often
un-recognized and under-treated. While patients with other long-term conditions such as diabetes are invited for routine
reviews in primary care, which may include identification and management of co-morbidities, at present this does not
occur for patients with inflammatory conditions, and thus, opportunities to diagnose and optimally manage these
comorbidities are missed. Objective: To evaluate the feasibility and acceptability of a nurse-led integrated care review
(the INtegrating and improving Care for patients with infLammatory rheUmatological DisordErs in the community
(INCLUDE) review) for people with inflammatory rheumatological conditions in primary care. Design: A pilot cluster
randomized controlled trial will be undertaken to test the feasibility and acceptability of a nurse-led integrated primary
care review for identification, assessment and initial management of common comorbidities including cardiovascular
disease, osteoporosis and anxiety and depression. A process evaluation will be undertaken using a mixed methods
approach including participant self-reported questionnaires, a medical record review, an INCLUDE EMIS template,
intervention fidelity checking using audio-recordings of the INCLUDE review consultation and qualitative interviews with
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patient participants, study nurses and study general practitioners (GPs) Discussion: Success of the pilot study will be
measured against the engagement, recruitment and study retention rates of both general practices and participants.
Acceptability of the INCLUDE review to patients and practitioners and treatment fidelity will be explored using a parallel
process evaluation. Trial Registration: ISRCTN12765345.
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Background
The impact of inflammatory rheumatic conditions includ-
ing rheumatoid arthritis (RA), psoriatic arthritis (PsA),
ankylosing spondylitis (AS), polymyalgia rheumatica
(PMR) and giant cell arteritis (GCA) for patients extends
far beyond the musculoskeletal system. Patients with these
conditions are at an increased risk of common comorbid-
ities such as cardiovascular disease (CVD), osteoporosis
and depression,1–6 leading to increased morbidity and mor-
tality, which is likely to be due to pre-existing lifestyle
factors (e.g. smoking) plus the disease physiology and its
treatment. Multimorbidity, the co-occurrence of two or
more long-term conditions (LTCs), is increasingly com-
mon.7 People with multimorbidity have reduced quality
of life and poorer clinical outcomes, despite using signifi-
cant health resources and as such effective management of
these patients is a priority area for future research. For
patients with inflammatory rheumatological conditions,
such as RA, these morbidities (particularly CVD, osteo-
porosis and depression) are more common and more
severe,8 but crucially often less well managed than in the
general population.9 Despite advances in the treatment of
RA, excess mortality remains, highlighting the need for
aggressive management of comorbidities.10
There is a progressive move towards providing inte-
grated care in primary care settings, rather than specialist
care. Such community-delivered care is frequently nurse-
led and aims to provide not only assessment and treatment
for the ‘index’ LTC but also a holistic assessment of other
comorbid conditions. In UK primary care, management of
many LTCs (including diabetes and CVD) is incentivized
by the quality and outcomes framework (QOF) component
of the GP contract, leading to an improved process of care
for those selected QOF conditions,11 although inflamma-
tory rheumatological conditions are not included within
QOF. Hence, routine primary care monitoring of these con-
ditions is not routine, with the exception of RA, where an
annual review is a target within QOF although the content
of the review is not specified. At present, NICE guidance
advocates people with RA should have an ‘annual review’
with a holistic assessment of their condition plus assess-
ment for associated comorbidities (e.g. CVD and osteo-
porosis).12 However, this is often fragmented between
primary and secondary care, resulting in duplication of
some screening, for example, CVD (with cost implica-
tions), while other morbidities remain unrecognized and
hence untreated. We have previously shown that primary
care RA annual reviews focus on CVD and osteoporosis
screening (as previous QOF domains) while other key hol-
istic elements, such as case finding for depression, are lack-
ing13 meaning opportunities for intervention are missed.14
Nurse-led care is increasingly advocated for manage-
ment of chronic inflammatory arthritis to increase the num-
ber of interventions taken to treat related morbidities.15,16
To date much of this has been delivered in specialist rheu-
matology services rather than primary care, but given the
multimorbidity expertise in primary care,17 we hypothesize
that delivering nurse-led integrated care reviews for
patients with inflammatory rheumatological conditions
may provide both patient and cost benefits while enabling
earlier identification, intervention and management of mul-
timorbidities. While RA is one of the commonest inflam-
matory rheumatic disorders consulted for in primary care,18
and to date has been studied most frequently with regard to
impact and assessment of comorbidities,1,3,5,14–16 given
that similar comorbidities occur across other inflammatory
conditions1–6 we aimed to assess whether such an approach
would be feasible across a broader range of inflammatory
rheumatological conditions.
Aims and objectives
The overall aim of this pilot study is to evaluate the feasi-
bility and acceptability of a nurse-led integrated care
review for people with inflammatory rheumatological con-
ditions in primary care. The primary objective for this pilot
study will be to assess the feasibility of conducting a larger
scale randomized controlled trial (RCT) by evaluating:
– the overall engagement, recruitment and study reten-
tion rates of both general practices and participants;
– the feasibility and acceptability of delivering the
INtegrating and improving Care for patients with
infLammatory rheUmatological DisordErs in the
community (INCLUDE) review for both patients
and practitioners.
Secondary objectives are to estimate the parameters
needed for a realistic sample size calculation for a defini-
tive RCT. Decision-making about progression to a full trial
will also be informed by the process evaluation, which will
examine the acceptability of the intervention as well as
assess the fidelity of the intervention delivery. The
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development of the study protocol followed the Standard
Protocol Items: Recommendations for Interventional Trials
guidelines19 and was developed in accordance with pub-
lished definitions of pilot and feasibility studies.20
Methods
Patient and practitioner involvement and engagement
The study was developed with input from the Haywood
User Group and Research User Groups at Keele. A specific
patient and practitioner involvement and engagement
(PPIE) group has met to discuss the purpose and content
of the proposed intervention to identify patient priorities
(which were agreed as CVD, osteoporosis and mood) and
to develop and review the questionnaire content. Key
health professional stakeholders (primary care, rheumatol-
ogy and nursing) have participated in an expert group to
discuss practicalities of implementing the review and
ensure that relevant QOF metrics (e.g. CVD) are captured.
Following these, an evidence-based template (INCLUDE
computer template based in EMIS GP software) has been
produced to support the integrated care review.
Design and setting
The INCLUDE study is a multicentre pilot cluster feasibility
study in UK primary care with parallel process evaluation.
General practices will be recruited from West Midlands
North via the National Institute for Health Research (NIHR)
Clinical Research Network (CRN). The units of randomiza-
tion will be the general practices and the units of observation
will be adults aged 18 years and older who have a Read code
for one of the five inflammatory rheumatic conditions of
interest (RA, PsA, AS, PMR and/or GCA).
Participants
GP practices. GP practices will be recruited through NIHR
CRNWest Midlands North. Practices are eligible for inclu-
sion if they use the clinical operating system EMIS Web
and are willing to take part and provide clinic facilities for
the recruitment period.
The balance between scientific considerations and the
need for consent is a recognized issue in cluster trials.21–24
Following discussion with their practice team, the senior GP
partner in each practice will provide informed consent for the
practice to participate, acting as ‘guardian’ for patients and
their care. GP practice consent to participate will be forma-
lized throughwritten agreements. To avoid selection bias and
differential consent, the inclusion and exclusion criteria will
be agreed and applied with all participating practices prior to
practice sign up and randomization in the study.
Randomization. Randomization to the intervention or con-
trol group will be performed at GP practice level using
stratified block randomization; stratification will be by
practice size (splitting by order of highest/lowest practice
sizes) and using block sizes of 2 and/or 4 within each
stratum to ensure balanced clusters and individual patient
numbers across study arms.
Patients within control practices will continue to receive
usual care from their GP practice. Eligible patients within
intervention practices will be invited to attend a nurse-led
integrated care review (the INCLUDE review) which
includes case finding and assessment for common comor-
bidities such as CVD, osteoporosis and anxiety and depres-
sion. The groups will be compared to assess the potential
effect of the intervention on a series of outcome measures
assessed by questionnaire. Measurements will take place at
baseline, 3 and 6 months.
Patient eligibility criteria. Patients will be eligible if they are
adults aged 18 years and older registered with a participat-
ing general practice who have a Read code in their elec-
tronic record for one of the five inflammatory rheumatic
conditions of interest (RA, PsA, AS, PMR or GCA) and are
capable of giving written informed consent in English.
Practice lists will be screened by the lead GP for each
practice, prior to randomization of the practice, and vulner-
able patients (e.g. patients on the practice register for
severe enduring mental health problems or significant cog-
nitive impairment (such as dementia) and/or in the pallia-
tive phase of their illness) will be excluded, as will people
who reside in a nursing home as alternative arrangements
will be in place for their long-term care.
Study procedures. The study flow chart is summarized in
Figure 1. Eligible patients at both control and intervention
practices will be sent a study baseline pack which includes
an invitation letter, Patient Information Sheet, Baseline
Questionnaire with consent form and prepaid return envel-
ope in the post from their GP practice. They will be asked
to complete and return the questionnaire and consent form.
To maximize response rates, reminder postcards will be
sent after 2 weeks and a reminder invitation pack will be
sent after 4 weeks. The same procedure will be followed for
both intervention and control practices. Patients who do not
respond or consent at baseline will be considered non-
responders or decliners, respectively, and will be not be
contacted again. Participants who consent and self-report
that they have one of the above named conditions will
remain in the study unless they request to be withdrawn.
Participants who consent at baseline but self-report that
they do not have one of the conditions of interest will be
deemed ineligible for the study and excluded. All respon-
ders who provide their contact details and consent to the
trial at baseline will be sent a postal questionnaire at 3 and 6
months, with reminder mailings following the same proce-
dure as at baseline. Participants will be asked to consent to
medical record review. Full general practice medical records
of consenting participants will be accessed and securely
downloaded to obtain information on consultations,
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prescriptions, investigations and referrals in the medical
records at 12 months.
Usual care.All participants (in both intervention and control
arms) will continue to receive usual GP care from their
general practice (and specialist care if appropriate) for the
duration of the study.
Intervention practices. In addition to the questionnaires
mailed to all participants, patients from intervention prac-
tices who have consented to participate in the study will
also be invited to attend an INCLUDE review appointment
(the intervention) to take place at their GP practice. This
will be a patient-centred consultation, delivered by an
INCLUDE study nurse trained to include case finding,
identification and assessment of CVD, anxiety and depres-
sion and osteoporosis. Outcome measures used in the ques-
tionnaire and review are summarized in Table 1. The
review will be recorded using an EMIS template specifi-
cally developed for the study. Patients will agree an
individualized management plan, which could include pro-
vision of written advice, self-management support and
Figure 1. Study flow chart.
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signposting/referral to appropriate services (e.g. blood
pressure monitoring within practice) and be provided with
a summary card sheet at the end of the consultation for
information.
Data collection
Questionnaire outcome measures. Table 1 illustrates the out-
come measures to be collected at each time point. In order
to retain patients’ anonymity, all data will be non-
identifiable and stored in password-protected, encrypted
files, separate from signed consent forms. Key domains will
include health-related quality of life (EQ-5D-5L),25,26 pain
intensity (numerical rating scale 0–10), physical function
Modified Health Assessment Questionnaire (MHAQ),27 fati-
gue Functional Assessment of Chronic Illness Therapy
(FACIT),28 anxiety General Anxiety Disorder 7 (GAD7)29
and depression Patient Health Questionnaire 8 (PHQ8),30,31
Patient Activation Measure,32 Multimorbidity Treatment
Burden Questionnaire33 and self-efficacy for Managing
Chronic Disease.34 Items measured at follow-up only will
include treatment acceptability and credibility,35 patient
satisfaction General Practice Assessment Questionnaire
(GPAQ)36 and healthcare utilization.
INCLUDE review data. At the INCLUDE review, the nurse
will conduct a holistic consultation to include case finding,
identification and assessment of CVD (QRISK2),37 obesity
(assessing body mass index), osteoporosis Fracture risk
assessment tool (FRAX)38 and anxiety and depression
(GAD2 and PHQ2 with full measures used as appropri-
ate).29–31 Outcomes in terms of an individualized manage-
ment plan will be recorded with the patient being provided
with a summary sheet at the end of the consultation for
Table 1. Outcome measures and data collection time points.
Schedule of assessments and outcome measures Baseline
INCLUDE
review
(intervention only)
Follow-up
(3 months)
Follow-up
(6 months)
Medical record
review
(12 months)
Inflammatory condition (checklist) x x x
General health
Comorbidities (checklist) x x
Impact of your inflammatory condition
Pain, stiffness, fatigue (numerical rating scale) x x x
Drug treatments for your condition x x
General health and mood
EQ-5D-5L x x x
Physical function (MHAQ) x x
Fatigue (FACIT) x x
GAD-7 x x
PHQ-8 x x
Your understanding of your health condition
Patient activation measure x x
Multimorbidity Treatment Burden Questionnaire x x x
Self-efficacy measure x x
Treatment acceptability and credibility x x
GPAQ (www.gpaq.org) x
Participant demographics
Demographics (DoB, gender, and ethnicity) x x
Lifestyle (employment, smoking, and alcohol) x x
Interventions since last questionnaire x x
INCLUDE computer template
Weight x x
Height x x
Waist circumference x
Blood pressure x
Cardiovascular disease risk (QRISK2) x
Fracture risk assessment tool (FRAX) x
GAD-2 x
PHQ-2 x
Medical record review
Symptoms x
Diagnoses x
Prescriptions x
Investigations x
Referrals x
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information. The review will be recorded using a study
specific EMIS computer template (the INCLUDE tem-
plate) which has been developed with primary care clini-
cians and health informatics specialists. This INCLUDE
template will be saved as part of the patient’s clinical care
record within EMIS at the GP practice. The data will be de-
identified, downloaded and securely transferred to Keele
Clinical Trials Unit (CTU) for analysis.
Medical record review. Entire set of general practice medical
records of consenting participantswill be accessed and securely
downloaded at 12 months after baseline, to obtain information
on consultations, prescriptions, investigations and referrals.
Process evaluation. A sample of participants attending the
INCLUDE reviewwill be asked to provide informed consent
to the intervention being audio-recorded (to assess fidelity of
delivery of the intervention). Face-to-face written consent
will be obtained by a researcher in the practice waiting room
prior to the review. On consent, the participant will be pro-
vided with an audio recording card (confirming consent
given) to hand to the study nurse. To assess perceptions of
acceptability of the review, semi-structured interviews
(either face-to-face or by telephone) will be undertaken with
a purposive sample of participants following their atten-
dance at the INCLUDE review.Where an INCLUDE review
consultation has been recorded, the method of tape-assisted
recall (TAR)39 will be used to prompt discussion in these
interviews. All the study nurses and GPs will also be invited
to participate in semi-structured interviews. The study nurses
will be interviewed twice – once after training to explore
their views of the training delivered prior to the start of the
study, and again at the end of the intervention period to focus
on perceptions of acceptability and feasibility of the
INCLUDE review. In these interviews, TAR will be used
to stimulate discussion. The topic guide for GP interviews
will explore the acceptability, feasibility and impact on rou-
tine practice of the INCLUDE review.
Sample size. As this is a pilot trial, a formal sample size
calculation is not required. Informed by previouswork exam-
ining consultation rates for inflammatory disorders in primary
care,18 we aim to recruit approximately 100 participating
individuals per arm to ensure that the range of conditions are
represented. To achieve this desired sample size, we estimate
that 200 patients will need to be invited per arm, allowing for
approximately 50% (n ¼ 100) consenting to participate.
These assumptions are based on trials with similar recruit-
ment methodology conducted at our research centre previ-
ously and will be tested in this pilot trial. We estimate that
between two and six GP practices per arm (depending on
practice size and demographics) will be required.
Data analysis plan
Quantitative analysis. As a pilot study, analysis will
be exploratory and focus upon process outcomes
(e.g. recruitment and retention and use of the INCLUDE
template). Descriptive statistics will be used to describe the
questionnaire response rates between the groups. Analysis
will focus on process outcomes (recruitment, retention,
intervention fidelity and change in practice through medi-
cal record review).
We will assess the number of potentially eligible
patients, number of eligible patients, consent rate, retention
rate and follow-up rates which will be presented in total and
stratified by study arm. The success of the pilot trial will be
assessed using criteria adapted from Avery et al.40:
a. Recruitment rates: Uptake of eligible patients
(red: <25%, amber: uptake 25–50% and Green:
uptake >50% of eligible patients);
b. Retention rates: follow-up rates across 3 and
6 months (red: <50%, amber: 50–70% and green:
follow-up rate > 70%);
c. Intervention uptake rates (i.e. patient uptake from
invitation to INCLUDE review; red: <30%,
amber: 30–50% and green: >50%).
We will summarize baseline patient characteristics by
study arm and will calculate means and confidence inter-
vals of outcome measures by study arm, and determine
which outcome is most sensitive to change over time, in
order to inform the sample size calculation for the main
trial. No formal statistical testing of superiority of clinical
outcome measures between treatment groups will be under-
taken: The study will retain a specific focus on assessing/
testing the feasibility of the design and methods towards
carrying out a main trial and of descriptive evaluation of
clinical measures.
Qualitative analysis. Researchers will listen to the audio-
recordings of the INCLUDE consultations and use a pre-
defined fidelity checklist specifically developed for the
study to assess intervention fidelity. A descriptive analysis
will be produced.
The qualitative interviews will be transcribed, and the
interview transcripts will form the data which will be ana-
lysed by members of the study team adopting a constant
comparison approach.41,42 Themes will be generated
through initial coding of text segments, followed by re-
coding with meetings between the team to enable discus-
sion and agreement of overarching themes. Triangulation
will allow us to compare qualitative and quantitative data in
order to give a greater understanding of how the interven-
tion was implemented. Data will also be mapped to the
domains of normalization process theory43 in order to
understand the context within which the INCLUDE inter-
vention was implemented in the pilot study.
Ethics approval and dissemination. The study was approved
by the Wales REC 5 Research Ethics Committee (REC
reference 17/WA/0427). Health Research Authority
approval for the study was obtained on 11 January 2018.
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All participants provided written informed consent. Patient
recruitment commenced on 21 March 2018 and is ongoing.
The research team intend to disseminate outcomes from the
study in peer-reviewed journals and at relevant confer-
ences. The main findings from the study will be available
on the Keele University website and displayed on posters in
participating GP practices. Participants will have access to
study results on request.
Study monitoring. An independent Trial Steering Committee
(TSC) has been appointed. Study monitoring will be con-
ducted according to a Trial Monitoring Plan developed by
the Trial Management Group based on the trial risk assess-
ment and in accordance with Keele CTU and Sponsor
Standard Operating Procedures, and agreed by the TSC.
Monitoring will also be undertaken by the approving
Research Ethics Committee in the format of annual prog-
ress reports and the NIHR Collaborations for Leadership in
Applied Health Research and Care West Midlands in the
format of quarterly progress reports. The study is deemed a
low-risk study since it uses a signposting intervention
already common in primary care for other patient groups.
As such, the outcomes being signposted from the
INCLUDE review are already used in routine clinical prac-
tice, and adverse events are uncommon and generally
minor. Study clinicians including GPs will be asked to
report unexpected and related adverse events and serious
adverse events they become aware of during the trial, with
the exception of planned hospitalizations, for a period of
3 months following the INCLUDE review only. Reporting
procedures will be made clear during the protocol study
training and will be contained in site files for all clinicians
involved in the study.
Discussion
Inflammatory rheumatological conditions such as RA, PsA,
AS, PMR or GCA are associated with a number of morbid-
ities such as CVD, osteoporosis, anxiety and depression
which impact negatively on quality of life, yet often these
comorbidities are under-recognized and treated.
This article describes the protocol for a pilot RCT with
parallel embedded process evaluation aiming to assess the
feasibility (eligibility, enrolment and retention rates, bar-
riers to recruitment, questionnaire completion rate and
intervention participation) and acceptability of a nurse-
led integrated care review (the INCLUDE review) for
patients with inflammatory rheumatological conditions in
primary care. PPIE has been integral to the development of
the study. Results from this study will inform decisions to
progress to a full-scale randomized control trial.
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